Rifafour
Sponsors
Global Alliance for TB Drug Development, National Institute of Allergy and Infectious Diseases (NIAID), TASK Applied Science, The Aurum Institute NPC
Conditions
Pulmonary TuberculosisTuberculosis
Phase 2
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
CompletedNCT01215851
Start: 2010-10-31End: 2011-08-31Updated: 2017-02-28
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
CompletedNCT01498419
Start: 2012-03-31End: 2013-07-31Updated: 2018-06-28
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
CompletedNCT01691534
Start: 2012-10-31End: 2013-05-31Updated: 2016-12-13
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
CompletedNCT03882177
Start: 2020-02-21End: 2022-12-31Updated: 2023-09-18
Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
CompletedNCT04629378
Start: 2020-08-17End: 2021-06-04Updated: 2022-01-25
A Pan-TB Regimen Targeting Host and Microbe
Active, not recruitingNCT05686356
Start: 2023-07-28End: 2026-01-31Target: 352Updated: 2025-05-28